Status:
COMPLETED
ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Purpura, Thrombocytopenic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The incidence of immune thrombocytopenia increases with older age. This population is at risk for arterial thrombosis. Due to an increased turn-over of platelets, low-dose aspirin once daily may be in...
Detailed Description
The incidence of immune thrombocytopenia increases with older age. About 20% of patients who develop immune thrombocytopenia are exposed to low-dose aspirin for arterial thrombosis prophylaxis. Moreov...
Eligibility Criteria
Inclusion
- adult patients
- non-treated immune thrombocytopenia or immune thrombocytopenia with stable treatment (at least 1 month)
- treated with aspirin daily for a cardiovascular disease; stable platelet count \< 100 x 109/L
- at least one month following an arterial thrombosis
- no other antiplatelet drug and anticoagulant
- female patient with childbearing potential must have acceptable method of birth control
- affiliated or benefiting from public health insurance
Exclusion
- opposition to participate
- adults under guardianship or other legal protection
- deprived of their liberty by judicial or administrative decision
- pregnancy or breastfeeding
Key Trial Info
Start Date :
January 16 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 2 2024
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT04912505
Start Date
January 16 2023
End Date
January 2 2024
Last Update
December 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Toulouse Hospital
Toulouse, France